STL Index for: Alefacept

Biologics plays an important role in treating moderate to severe psoriasis. This article looks at combination treatment with traditional systemics and topicals, and the possible benefits of this approach.

Biologic agents were introduced during the past decade as a new class of treatments for chronic psoriasis. This review will discuss data from clinical trials that have provided new insights into the efficacy, safety, and cost effectiveness of alefacept as a treatment for psoriasis.

In October 2004 Amevive® (alefacept) became the first biologic approved for psoriasis in Canada. It is used to treat moderate to severe psoriasis. This article discusses clinical trials, side effects, and drug interactions.

Moderate-to-severe psoriasis is known to affect millions of people around the globe. This chronic disease substantially impacts patients by impairing their quality of life. The biologics are the newest and most effective therapeutic weapon in the treatment of moderate-to-severe psoriasis and psoriatic arthritis.

Amevive (Alefacept), its side-effects, safety, and risks are discussed in this article. Potential adverse reactions and lab monitoring guidelines are also covered.

Compliance issues with Amevive (Alefacept) are discussed. The Amevive Care Program, and its scope and coverage are discussed.

Amevive (Alefacept) and its efficacy is discussed. Measurement techniques like PASI (for psoriasis), dermatology quality of life index are discussed as well as for psoriatic arthritis.

Amevive (Alefacept), clinical experience, patient profiles, indications, dosing and cost are discussed in this article.

Amevive® (Alefacept) and its clinical experience, and clinical evidence are discussed. As a biologic, safety profiles, and mechanisms of action are also covered.

The elderly population is increasing and drug dosing requires special considerations for efficacy and decreasing toxicity. This overview provides algorithms for adjusting drug and dosage based on current evidence-based knowledge with emphasis on drugs prescribed in dermatological practice.

Although the developing fetus was once considered protected from the outside world, we now know that it can potentially be affected by any medication given to the mother. Therapeutic options available for these patients will be discussed.

Alefacept (AMEVIVE™ or LFA3TIP, Biogen) is the newest systemic therapy for chronic plaque psoriasis and was approved by the US FDA in January 2003. Clinical studies have shown that alefacept, given via weekly IM or IV injections for 12 weeks, was well tolerated, with no reported serious adverse events.